目的:探讨CYP2C19基因多态性检测指导经皮冠状动脉介入术后患者氯吡格雷个体化用药的意义.方法:选取2015年1月-2016年7月漯河市中心医院收治的行经皮冠状动脉介入治疗的冠心病患者115例作为研究对象.采用基因芯片检测技术进行CYP2C19基因多态性检测,根据检测结果为患者制订个体化用药建议.结果:快代谢型患者53例,占46.09％,建议给予常规剂量的氯吡格雷;中代谢型患者47例,占40.87％,建议增加氯吡格雷剂量;慢代谢型患者15例,占13.04％,建议更换其他抗血小板药.结论:CYP2C19基因型存在个体差异,会引起使用氯吡格雷的患者出现疗效差异,因此应根据患者不同基因型制订个体化用药方案.%Objective:To probe into the significance of individualized medication of clopidogrel guided by CYP2C19 gene polymorphism test in patients after PCI.METHODS: 115 patients with coronary heart disease after PCI admitted into Luohe Central Hospital from Jan.2015 to Jul.2016 were extracted.CYP2C19 gene polymorphism test was conducted by gene chip detection technology.Suggestions were provided for individualized medication by the determination results.RESULTS: There were 53 cases of rapid metabolic type,accounting for 46.09％,conventional doses of clopidogre were suggested to take;47 cases were intermediate metabolic type,accounting for 40.87％,dose of clopidogrel were suggested to increase;in addition,15 cases were slow metabolic type,accounting for 13.04％,other antiplatelet drugs were suggested to replace.CONCLUSIONS: There are individual differences in CYP2C19 genotype,which can cause differences in the efficacy of clopidogrel,and the doctor should formulate individualized medication for patients base on different genotype.
展开▼
